• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (CSE: MDMA )

    0.1150 +0.0050 (+4.55%)
    Streaming Delayed Price Updated: 1:05 PM EDT, Jul 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 49,265
    Open 0.1150
    Bid (Size) 0.1150 (10,000)
    Ask (Size) 0.1200 (15,500)
    Prev. Close 0.1100
    Today's Range 0.1150 - 0.1200
    52wk Range 0.0850 - 0.4000
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale
    Red Light Holland and PharmAla achieve psilocybin extraction milestone, advancing API development for scalable medical products. Read now! 
    Via Benzinga
    Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
    Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
    From PharmAla Biotech
    Via GlobeNewswire

    Performance

    YTD
    -23.33%
    -23.33%
    1 Month
    -4.17%
    -4.17%
    3 Month
    -48.89%
    -48.89%
    6 Month
    -30.30%
    -30.30%
    1 Year
    -70.13%
    -70.13%

    More News

    Read More
    Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
    From PharmAla Biotech
    Via GlobeNewswire
    Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
    From PharmAla Biotech
    Via GlobeNewswire
    Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
    From PharmAla Biotech
    Via GlobeNewswire
    PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
    From PharmAla Biotech
    Via GlobeNewswire
    PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
    From PharmAla Biotech
    Via GlobeNewswire
    PharmAla Begins Trading on OTCQB
    From PharmAla Biotech
    Via GlobeNewswire
    PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
    From PharmAla Biotech
    Via GlobeNewswire
    Life Science Investor Forum: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    Life Science Investor Forum Agenda Announced for June 22nd
    From Virtual Investor Conferences
    Via GlobeNewswire
    USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
    From PharmAla Biotech
    Via GlobeNewswire
    PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
    From PharmAla Biotech
    Via GlobeNewswire
    Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
    From PharmAla Biotech
    Via GlobeNewswire
    The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
    Via ACCESSWIRE
    KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    PharmAla Completes Pre-IND Meeting with FDA, to Present at KCSA Virtual Investor Conference
    From Virtual Investor Conferences
    Via GlobeNewswire
    KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
    From Virtual Investor Conferences
    Via GlobeNewswire
    Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
    From PharmAla Biotech
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.